Clarion News

Perspectives from the 2018 ESMO Congress


Clarion joined over 28,000 attendees in Munich at this year’s ESMO Annual Congress to learn about the latest advances in cancer therapeutics and clinical care. From over 2000 presentations and posters, we present here selected highlights, including phase 3 data for first-in-class new therapies for breast cancer, pivotal data for new first-line treatments in other tumor types, and a sampling of the wide-ranging discussions and continuing advances in the field of immuno-oncology.

ESMO 2018 meeting summary and Clarion perspectives

Is Clarion the right place to advance your career?

Find out more about joining Clarion’s team of innovation advisors.

A life sciences strategy and organizational consultancy that collaborates with its clients to envision, craft and enable growth through innovation and leadership.